Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice
Por:
Santos, A, Resmini, E, Martinez-Momblan, MA, Crespo, I, Valassi, E, Roset, M, Badia, X, Webb, SM
Publicada:
1 sep 2012
Resumen:
Objective: To evaluate health-related quality of life (HRQoL) in Cushing's syndrome (CS) with the disease-generated CushingQoL questionnaire and to confirm its psychometric properties of test-retest reliability and sensitivity to change.
Design: Clinical practice conditions in a tertiary referral center.
Methods: The CushingQoL and EuroQoL questionnaires were administered at baseline and during follow-up and correlated with clinical parameters in 59 patients with CS. To check test-retest reliability, stable patients (either biochemically cured or with active hypercortisolism) were evaluated twice. To investigate sensitivity to change, new patients were evaluated at diagnosis and twice more following improvement after successful surgery.
Results: At baseline, patients with active disease scored lower (indicating worse HRQoL) than those cured on the CushingQoL (46 +/- 14 vs 58 +/- 20, P<0.05) but not on the EuroQoL-visual analog scale (VAS; 64 +/- 20 vs 70 +/- 16, P NS). Test-retest reliability of CushingQoL was confirmed in stable patients, both in the 'cured group' (intraclass correlation coefficient (ICC)=0.78, n=34) and in the 'active group' (ICC=0.66, n=14). Sensitivity to change was confirmed in the 'improvement group' (n=11), as the CushingQoL score increased 4 +/- 1.5 and 9 +/- 3 months after surgery (P<0.01 and <0.001 respectively); the EuroQoL-VAS only improved after 9 +/- 3 months (P<0.01). Effect sizes were 1.02 and 1.86 for CushingQoL at 4 +/- 1.5 and 9 +/- 3 months respectively. Finally, scores of both questionnaires were correlated (r=0.504; P<0.001).
Conclusions: The CushingQoL questionnaire shows good test-retest reliability and sensitivity to change in clinical practice conditions.
Filiaciones:
Santos, A:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Resmini, E:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Martinez-Momblan, MA:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Crespo, I:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Valassi, E:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Roset, M:
IMS Hlth, Hlth Econ & Outcomes Res, Barcelona, Spain
Badia, X:
IMS Hlth, Hlth Econ & Outcomes Res, Barcelona, Spain
Webb, SM:
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Endocrinol Dept, Barcelona 08025, Spain
UAB, ISCIII,Unit 747, Ctr Invest Biomed Red Enfermedades Rares CIBERER, IIB St Pau,Hosp St Pau,Med Dept, Barcelona 08025, Spain
Bronze
|